Oncotarget

Corrections:

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

PDF  |  How to cite

Oncotarget. 2024; 15:142-142. https://doi.org/10.18632/oncotarget.28523

Metrics: PDF 262 views  |   ?  

Maryam Zanjirband1, Nicola Curtin1, Richard J. Edmondson2 and John Lunec1

1Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom
2Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom

Published: February 22, 2024

Copyright: © 2024 Zanjirband et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5, the actin band in the A2780 column contains a partial duplicate of the same band in the IGROV-1 column. The corrected Figure 5, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:69779–69796. DOI: https://doi.org/10.18632/oncotarget.19266

Figure 5: Combination of Nutlin-3/RG7388 with rucaparib increased upregulation of TP53 downstream target, PUMA compared to rucaparib on its own but not compared to Nutlin-3/RG7388. Total levels of PUMA 24 hours after the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with rucaparib at constant 1:1 ratios of 1X their respective GI50 concentration analyzed by western blot in three wild-type TP53 ovarian cancer cell lines.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28523